Answers are grounded in this paper and cite their sources.
The FDA's alerts regarding the T-cell lymphoma risk post CAR-T therapy has garnered global attention, yet a comprehensive profile of second primary malignancies (SPMs) following CAR-T treatment is lacking.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: